Objectives Currently, no consensus exists regarding the optimal oral prophylactic regimens
for hepatitis B surface antigen seropositive patients undergoing chemotherapy. We aimed to …

Background: We aimed to evaluate the efficacy of five oral nucleos (t) ide analogues (NAs),
including lamivudine, entecavir, adefovir, telbivudine and tenofovir, for the prevention of …

Background/Aims: Studies have shown that nucleos (t) ide analogue (NA) treatment can
reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients, but …

Background It has been proved that nucleos (t) ide analogues (NAs) therapy could improve
underlying liver disease and reduce the incidence of hepatitis B virus (HBV)-related …

HBV reactivation (HBVr) can be prevented by nucleos (t) ide analogues (NAs). We
conducted a systematic review and meta-analysis on the risk of HBVr associated with new …

Hepatocellular carcinoma (HCC) is among the most common cancer types and causes of
cancer related mortality worldwide. Almost 50% of all HCC cases globally are attributable to …

The hepatitis B virus (HBV) infection remains a global public health problem. This review
presents updated recommendations for the optimal current treatment of choice with nucleos …

Nucleos (t) ide analogues (NAs) are the main drug category used in chronic hepatitis B
(CHB) treatment. Despite the fact that NAs have a favourable safety profile, undesired …

Studies in the past decades have shown that active hepatitis B virus (HBV) replication is the
key driver of liver injury and disease progression, and thus sustained viral suppression is of …

Summary Background North American data are lacking on the effect of nucleos (t) ide
analogues (NA) in preventing chronic hepatitis B (CHB)‐related hepatocellular carcinoma …